Pharmaceutical News

RSS

Arthritis pain relief drug ALEVE now available OTC in British Columbia

This winter, British Columbians may be inspired to increase their activity level and take part in some favourite winter pastimes. For those who have joint and arthritis pain, getting back to doing the activities they love may be more of a challenge. ALEVE(R) is the first over-the-counter naproxen sodium tablet, and is now available province-wide. With just one pill, ALEVE(R) offers convenient access to pain relief for up to 12 hours.

29 Jan 2010

AccuDial Pharmaceutical introduces eight new OTC medications in Canada

AccuDial® Pharmaceutical, Inc. delivered a power-packed launch with their new family of eight over-the-counter (OTC) medications in Canada. Colorful floor displays enjoyed prominent placement in every Quebec Walmart pharmacy, and were filled with AccuDial's pain and fever, allergy, and cough and cold pediatric medications.

29 Jan 2010

Labeling update for Tibotec Therapeutics' PREZISTA tablets approved

Tibotec Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a labeling update for PREZISTA® (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies.

29 Jan 2010

Regis Technologies' 4-Aminopyridine manufacturing facility receives FDA's EIR and PAI approval

Regis Technologies, Inc., a leading provider of cGMP and non-GMP synthesis and separations services for active pharmaceutical ingredients (APIs) and intermediates, announced it has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) stating that Regis passed the FDA’s pre-approval inspection (PAI) for its manufacture of 4-Aminopyridine the active ingredient in Ampyra™.

29 Jan 2010

FDA approves LPI's Perindopril Erbumine tablets

Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the U.S. Food and Drug Administration (U.S. FDA) for its Perindopril Erbumine tablets, 2mg, 4mg and 8mg. Commercial shipments of the product will commence shortly.

29 Jan 2010

Rotavirus vaccine could save millions of children in developing countries, studies find

Efforts to vaccinate "infants against rotavirus could save the lives of millions of children in developing nations who would otherwise die from the diarrhea-causing disease, two new studies show," HealthDay/BusinsessWeek reports.

28 Jan 2010

FDA cautions drug makers about potential abuse

The Los Angeles Times reports that the Food and Drug Administration "this week released a draft of voluntary guidelines to assist drug makers in figuring out which compounds should be placed under the Controlled Substances Act. The law regulates the handling, record-keeping and dispensing of drugs deemed to be dangerous or addictive if misused -- in some cases imposing criminal penalties for misuse.

28 Jan 2010

UNICEF and IZA launch “Zinc Saves Kids” campaign

UNICEF and the International Zinc Association (IZA) announced today the launch of the “Zinc Saves Kids” campaign. The initiative will raise funds to support UNICEF’s zinc supplementation programs for children in developing countries.

28 Jan 2010

Aubrey receives FDA clearance to market bioengineered wound dressings in U.S.

Aubrey Inc., an advanced wound care company, announced it has received clearance from the US Food and Drug Administration (FDA) to market the AWBAT Plus product line in the United States.

28 Jan 2010

Oculus Innovative Sciences introduces Microcyn Solution for treatment of post-surgical wounds

Oculus Innovative Sciences, Inc., a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, today unveiled Microcyn Solution with preservatives, at the New York Podiatric Clinical Conference & Exhibition being held in downtown Manhattan, January 29-31.

28 Jan 2010

Merck’s sales representatives ranked second by cardiologists

According to SDI’s recently released 2009 Ranking Tables Study, Merck’s sales representatives were ranked second by cardiologists, a noteworthy increase from sixth place in 2008. Pfizer was ranked first by cardiologists. Schering-Plough, AstraZeneca, and Novartis rounded out the top five, finishing third, fourth, and fifth, respectively.

28 Jan 2010

Men welcome male contraceptive pill currently undergoing trials

Would you trust men to take a 'male pill'? That's the question posed to 380 people in North East England by a team from Teesside University which questioned people about the male contraceptive pill currently undergoing trials.

28 Jan 2010

Studies in Mexico and Africa demonstrate the effectiveness of rotavirus vaccine

For the first time ever, studies in Mexico and Africa, published today in the New England Journal of Medicine, demonstrate a reduction in diarrheal disease deaths following rotavirus vaccine introduction in Mexico and vaccine efficacy among impoverished populations in Malawi and South Africa.

28 Jan 2010

Repligen announces five-year supply agreement for recombinant Protein A with GE Healthcare Bio-Sciences

Repligen Corporation announced today that it has extended its longstanding relationship with GE Healthcare Bio-Sciences AB by entering into a five-year supply agreement for recombinant Protein A, a consumable used in the manufacture of monoclonal antibodies, a highly successful class of biopharmaceutical. Repligen is the world's leading supplier of recombinant Protein A and has manufactured recombinant Protein A for GE Healthcare for more than 10 years.

28 Jan 2010

Formatech donates $308K in aseptic liquid fill and finish manufacturing services

Formatech continues its pledge to give back and make a difference in the biotechnology and pharmaceutical community with its Fillanthropy Program. Since the program’s inception, Formatech has donated $308K in aseptic liquid fill and finish manufacturing services to companies developing new drug therapies.

28 Jan 2010

Onset Therapeutics expands its sales force to create nationwide presence

Onset Therapeutics LLC, a specialty pharmaceutical company focused in dermatology, today announced that the Company’s recent growth and future opportunities have facilitated an expansion of its field sales organization to cover more than twenty-five additional major metropolitan areas.

28 Jan 2010

Particle Sciences to share responsibilities in developing anti-HIV microbicides

Particle Sciences, a leading drug development CRO, will share formulation, analytic and production responsibilities in an effort to develop a vaginally administered microbicide, a product specifically designed to prevent the sexual transmission of HIV.

28 Jan 2010

Pfizer's new pipeline shows growth and diversity in research and development

Pfizer Inc. today provided an update to its pipeline for the first time since the close of the acquisition of Wyeth in October, 2009. The new development pipeline, composed of assets from both legacy companies, includes 133 programs from phase 1 through registration, and shows growth and increased diversity in each of the areas where the company invests in research and development.

28 Jan 2010

Alli boosts weight loss and reduces excess visceral fat

New studies show that overweight and obese people using alli® (orlistat 60 mg) with a reduced calorie, lower-fat diet can significantly reduce weight, visceral fat, and waist circumference and therefore may reduce their risk of type 2 diabetes, hypertension, heart disease and stroke.

28 Jan 2010

Transdermal estrogen therapies: Effective alternatives to oral estrogen and compounded bioidentical hormones

Clinical and experimental evidence suggests that non-patch, transdermal estrogen therapies, such as Divigel® (estradiol gel 0.1%), prescribed for the management of moderate-to-severe hot flashes, including night sweats, associated with menopause are effective alternatives to oral estrogen and compounded bioidentical hormones.

28 Jan 2010